JP2018533601A5 - - Google Patents

Download PDF

Info

Publication number
JP2018533601A5
JP2018533601A5 JP2018524369A JP2018524369A JP2018533601A5 JP 2018533601 A5 JP2018533601 A5 JP 2018533601A5 JP 2018524369 A JP2018524369 A JP 2018524369A JP 2018524369 A JP2018524369 A JP 2018524369A JP 2018533601 A5 JP2018533601 A5 JP 2018533601A5
Authority
JP
Japan
Prior art keywords
oral pharmaceutical
pharmaceutical formulation
formulation according
oral
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018524369A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018533601A (ja
JP7294807B2 (ja
Filing date
Publication date
Priority claimed from US15/133,087 external-priority patent/US20160338982A1/en
Application filed filed Critical
Priority claimed from PCT/US2016/061678 external-priority patent/WO2017083758A1/en
Publication of JP2018533601A publication Critical patent/JP2018533601A/ja
Publication of JP2018533601A5 publication Critical patent/JP2018533601A5/ja
Priority to JP2021213640A priority Critical patent/JP2022058446A/ja
Application granted granted Critical
Publication of JP7294807B2 publication Critical patent/JP7294807B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018524369A 2015-11-13 2016-11-11 L-オルニチンフェニルアセテート製剤 Active JP7294807B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021213640A JP2022058446A (ja) 2015-11-13 2021-12-28 L-オルニチンフェニルアセテート製剤

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562255300P 2015-11-13 2015-11-13
US62/255,300 2015-11-13
US201662276754P 2016-01-08 2016-01-08
US62/276,754 2016-01-08
US15/133,087 2016-04-19
US15/133,087 US20160338982A1 (en) 2015-04-20 2016-04-19 Formulations of l-ornithine phenylacetate
PCT/US2016/061678 WO2017083758A1 (en) 2015-11-13 2016-11-11 Formulation of l-ornithine phenylacetate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021213640A Division JP2022058446A (ja) 2015-11-13 2021-12-28 L-オルニチンフェニルアセテート製剤

Publications (3)

Publication Number Publication Date
JP2018533601A JP2018533601A (ja) 2018-11-15
JP2018533601A5 true JP2018533601A5 (ru) 2019-12-19
JP7294807B2 JP7294807B2 (ja) 2023-06-20

Family

ID=58695607

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018524369A Active JP7294807B2 (ja) 2015-11-13 2016-11-11 L-オルニチンフェニルアセテート製剤
JP2021213640A Pending JP2022058446A (ja) 2015-11-13 2021-12-28 L-オルニチンフェニルアセテート製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021213640A Pending JP2022058446A (ja) 2015-11-13 2021-12-28 L-オルニチンフェニルアセテート製剤

Country Status (12)

Country Link
EP (1) EP3373923A4 (ru)
JP (2) JP7294807B2 (ru)
KR (1) KR20180086431A (ru)
CN (2) CN108366983A (ru)
AU (2) AU2016353350B2 (ru)
BR (1) BR112018009349A8 (ru)
CA (1) CA3004331A1 (ru)
IL (1) IL258630B2 (ru)
MX (2) MX2018005088A (ru)
RU (1) RU2018113801A (ru)
SG (1) SG11201802987UA (ru)
WO (1) WO2017083758A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
WO2019036471A1 (en) 2017-08-14 2019-02-21 Axcella Health Inc. AMINO ACIDS BRANCHED FOR THE TREATMENT OF LIVER DISEASE
JP2021527670A (ja) 2018-06-20 2021-10-14 アクセラ・ヘルス・インコーポレイテッドAxcella Health Inc. 筋肉中の脂肪浸潤の治療のための組成物及び方法
EP4045028A4 (en) * 2019-10-16 2023-11-08 Ocera Therapeutics, Inc. DOSAGE AND USES OF ORNITHINE PHENYLACETATE FOR THE TREATMENT OF HYPERAMMONEMIA

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
GB0426141D0 (en) * 2004-11-26 2004-12-29 Ucl Biomedica Plc Treatment
EA018007B1 (ru) * 2004-11-26 2013-04-30 Ю Си Эл БИЗНЕС Пи Эл Си Композиция, содержащая орнитин и фенилацетат или фенилбутират, для лечения печеночной энцефалопатии
DE102007009243A1 (de) * 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets
AU2015221466B2 (en) 2009-04-03 2017-02-02 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
EA023051B1 (ru) * 2009-04-03 2016-04-29 Осера Терапьютикс, Инк. Кристаллические формы фенилацетата l-орнитина и их применение
EP2440200B8 (en) * 2009-06-08 2014-10-15 UCL Business PLC Treatment of portal hypertension using l-ornithine phenylacetate
AU2014250643B2 (en) 2009-06-08 2016-07-14 Ocera Therapeutics, Inc. Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate
NZ609191A (en) * 2010-10-06 2015-06-26 Ocera Therapeutics Inc Methods of making l-ornithine phenyl acetate
CN103705490B (zh) * 2013-10-31 2016-08-17 蚌埠丰原医药科技发展有限公司 一种门冬氨酸鸟氨酸的缓释制剂及其制备工艺
DK3285756T3 (da) 2015-04-20 2023-05-08 Ocera Therapeutics Inc Formuleringer af l-ornithinphenylacetat

Similar Documents

Publication Publication Date Title
JP2018513171A5 (ru)
JP2015503593A5 (ru)
JP2018533601A5 (ru)
HRP20192133T1 (hr) Kemijski spoj koristan kao posrednik za pripremu inhibitora katekol-o-metiltransferaze
RU2017137643A (ru) Составы l-орнитин фенилацетата
RU2018114447A (ru) Введение дейтерированных усилителей cftr
FI3936130T3 (fi) Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon
JP2014111603A5 (ru)
JP2015083580A5 (ru)
JP2008520736A5 (ru)
FI3562486T3 (fi) Kielenalaisen deksmedetomidiinin käyttö agitaation hoidossa
JP2013505205A5 (ru)
RU2016124765A (ru) ПРИМЕНЕНИЕ ГИНЗЕНОЗИДА Rg3 В ПРИГОТОВЛЕНИИ ЛЕКАРСТВЕННОГО ПРЕПАРАТА ДЛЯ ПРОФИЛАКТИКИ И/ИЛИ ЛЕЧЕНИЯ ДЕМЕНЦИИ, И ЛЕКАРСТВЕННЫЙ ПРЕПАРАТ ДЛЯ ЛЕЧЕНИЯ ДЕМЕНЦИИ
CA2709997A1 (en) Pirfenidone treatment for patients with atypical liver function
BR122023026625A2 (pt) Uso do ácido 15-hidroxieicosapentaenoico ou derivados farmaceuticamente aceitáveis do mesmo
JP2016534081A5 (ja) ゾレドロン酸の増強された経口バイオアベイラビリティーを有する経口剤形を調製する方法
RU2018113801A (ru) Составы l-орнитин фенилацетата
MX2018000084A (es) Una composicion farmaceutica que comprende amlodipino, valsartan y rosuvastatina.
HRP20200473T1 (hr) Dimetilaminomikeliolid za uporabu u tretmanu pulmonarne fibroze
RU2018146504A (ru) Лечение внутрипеченочных холестатических заболеваний
IL272834B1 (en) Compositions of amantadine, their preparation, and methods of use
JP2015531749A5 (ru)
JP2016512247A5 (ru)
JP2017507142A5 (ru)
JP2017512194A5 (ru)